Cargando…

Predictive value of microvascular density for response to anlotinib in advanced NSCLC

Nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer. This study aimed to categorize the microvessels in advanced NSCLC and determine the relationship between intratumoral microvascular density (MVD) and the efficacy of anlotinib for NSCLC. The clinical data of 68 patients receiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Danqing, Ding, Guozheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772671/ https://www.ncbi.nlm.nih.gov/pubmed/35060554 http://dx.doi.org/10.1097/MD.0000000000028647

Ejemplares similares

Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report
por: Zhang, Aixia, et al.
Publicado: (2019)

Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports
por: Zhang, Pin-Liang, et al.
Publicado: (2019)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Recent death early warning value of ECG changes in patients with NSCLC
por: Liu, Qiong, et al.
Publicado: (2023)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution
por: He, Xiaobo, et al.
Publicado: (2016)

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
por: Qin, Jiqiu, et al.
Publicado: (2023)

Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
por: Liu, Liang, et al.
Publicado: (2021)

Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy
por: Cai, Jing, et al.
Publicado: (2021)

Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC: A Meta-Analysis
por: Chen, Zhenguang, et al.
Publicado: (2015)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety
por: Ye, Haiyong, et al.
Publicado: (2021)

Orbital adenoid cystic carcinoma treated by radiotherapy combined with anlotinib in a 13-year-old girl: A case report
por: Wu, Xue, et al.
Publicado: (2023)

Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
por: Lin, Chia-Ying, et al.
Publicado: (2019)

The prognostic and predictive value of the albumin-bilirubin score in advanced pancreatic cancer
por: Zhang, Tie-Ning, et al.
Publicado: (2020)

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
por: Gürbüz, Mustafa, et al.
Publicado: (2022)

Diagnostic value of microRNA-148/152 family in non-small-cell lung cancer (NSCLC): A systematic review and meta-analysis
por: Cheng, Long, et al.
Publicado: (2021)

Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis
por: Li, Juan, et al.
Publicado: (2020)

LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases: An Observational Study
por: Hu, Nan, et al.
Publicado: (2015)

First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis
por: Lan, Bo, et al.
Publicado: (2021)

The effect of the earliest COVID-19 outbreak on survival in uninfected advanced NSCLC patients receiving chemotherapy in Jiangsu Province, China: A retrospective cohort study
por: Lu, Heng, et al.
Publicado: (2023)

The Value of (18)F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
por: Luo, Jurui, et al.
Publicado: (2016)

The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Liu, Guo-Chen, et al.
Publicado: (2015)

Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report
por: Fricke, Jeremy, et al.
Publicado: (2020)

Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT
por: Pan, Yi, et al.
Publicado: (2015)

Gastric and colonic metastasis from NSCLC: A very unusual case report
por: Catalano, Martina, et al.
Publicado: (2022)

Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report
por: Ding, Xingchen, et al.
Publicado: (2017)

Effects of microvascular invasion on clinical outcomes after resection with curative intent for cholangiocarcinoma
por: Song, Bo-Hye, et al.
Publicado: (2020)

The predictive value of calcification for the grading of ductal carcinoma in situ in Chinese patients
por: Kong, Jianchun, et al.
Publicado: (2020)

Therapeutic effectiveness and safety of sequential ICIs with radiotherapy for symptomatic brain and bone metastases in NSCLC patients
por: Tang, Cuiping, et al.
Publicado: (2022)

Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
por: Qi, Nan, et al.
Publicado: (2016)

Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports
por: Lai, Lin, et al.
Publicado: (2021)

Construction of a 5 immune-related lncRNA-based prognostic model of NSCLC via bioinformatics
por: Huang, Ya-jie, et al.
Publicado: (2021)

A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations
por: Song, Si-Yeon, et al.
Publicado: (2020)

Prognostic value of fibrosis ratio in metastatic lymph nodes of node-positive advanced gastric cancer
por: Hong, Soon Auck, et al.
Publicado: (2018)

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

TCM therapies combined with chemotherapy for preventing recurrence and metastasis in postoperative II to IIIA NSCLC: A protocol for a systematic review and meta-analysis
por: Chen, Shuntai, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_chm6jq27ongh60gjnrau0el41g